Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lumacaftor + ivacaftor study in cystic fibrosis with homozygous F508del mutation
NL-OMON40417Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lumacaftor and ivacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change in percent predicted forced expiratory volume in 1 second. Started Aug 2013; status: active, not recruiting.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON40417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40417.